Skip to main content
Top
Published in: Neurological Sciences 12/2019

01-12-2019 | Magnetic Resonance Imaging | Review Article

The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis

Authors: Xiangming Wang, Yuehui Zhang, Chen Zhu, Guangzong Li, Jie Kang, Fang Chen, Ling Yang

Published in: Neurological Sciences | Issue 12/2019

Login to get access

Abstract

The main purpose of this study was to systematically evaluate the accuracy of neuromelanin-sensitive magnetic resonance imaging (NM-MRI) in Parkinson’s disease (PD) diagnosis using a meta-analysis method. In PubMed, Web of Science, Embase, and Google Scholar, the literatures were searched for the diagnostic value of neuromelanin-sensitive magnetic resonance imaging in PD. The literatures were screened in the light of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data analysis was processed by Stata 12.0 software to obtain meta-analysis, heterogeneity analysis, and publication bias. Meta-analysis results showed by using NM-MRI observed substantia nigra pars compacta (SNpc) on PD, the pooled diagnostic sensitivity and specificity were 0.82 (95% CI, 0.74–0.87) and 0.82 (95% CI, 0.73–0.89), respectively. And the pooled positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 4.58 (95% CI, 3.08–6.82) and 0.22 (95% CI, 0.16–0.31), respectively. Moreover, subgroup analysis according to the measurement criteria of SNpc showed the SNpc volume should be used as good a marker for diagnosing PD. Finally, Fagan test demonstrated that when PLR was equal to 5, the posterior probability is significantly enhanced to 53%, compared with prior probability (20%). As for NLR (0.22), the prior probability is 20%, while the posterior probability remarkably dropped to 5%. In conclusion, SNpc signal detected by NM-MRI exhibited high sensitivity and specificity for diagnosis of PD, which was a high-performance imaging diagnostic method for PD. We recommend NM-MRI imaging technology to be widely used in Parkinson’s diagnosis.
Literature
1.
go back to reference Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–324CrossRef Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–324CrossRef
2.
go back to reference Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, Li HH (2016) Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna) 123(12):1381–1386CrossRef Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, Li HH (2016) Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease. J Neural Transm (Vienna) 123(12):1381–1386CrossRef
3.
go back to reference Zou YM, Liu J, Tian ZY, Lu D, Zhou YY (2015) Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1467–1472CrossRef Zou YM, Liu J, Tian ZY, Lu D, Zhou YY (2015) Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1467–1472CrossRef
4.
go back to reference Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376CrossRef Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376CrossRef
5.
go back to reference Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134CrossRef Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134CrossRef
6.
go back to reference Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78CrossRef Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–78CrossRef
7.
go back to reference Zucca FA, Vanna R, Cupaioli FA, Bellei C, de Palma A, di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinsons Dis 4:17CrossRef Zucca FA, Vanna R, Cupaioli FA, Bellei C, de Palma A, di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinsons Dis 4:17CrossRef
8.
go back to reference Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 33(9):1488–1492CrossRef Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 33(9):1488–1492CrossRef
9.
go back to reference Pavese N. 2018 Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson’s disease that we were looking for? Parkinsonism Relat Disord. Pavese N. 2018 Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson’s disease that we were looking for? Parkinsonism Relat Disord.
10.
go back to reference Rovini E, Maremmani C, Moschetti A, Esposito D, Cavallo F (2018) Comparative motor pre-clinical assessment in Parkinson’s disease using supervised machine learning approaches. Ann Biomed Eng 46(12):2057–2068CrossRef Rovini E, Maremmani C, Moschetti A, Esposito D, Cavallo F (2018) Comparative motor pre-clinical assessment in Parkinson’s disease using supervised machine learning approaches. Ann Biomed Eng 46(12):2057–2068CrossRef
11.
go back to reference Zhang Z, Wang J, Chen S, Liu C, Zhang B, Peng R, Sun S, Sun X, Zhao G, Qu Q, Li Y, Zhu S, Pan X, Shao M, Wang Y (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener 7:32CrossRef Zhang Z, Wang J, Chen S, Liu C, Zhang B, Peng R, Sun S, Sun X, Zhao G, Qu Q, Li Y, Zhu S, Pan X, Shao M, Wang Y (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener 7:32CrossRef
12.
go back to reference Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 quiz 1837CrossRef Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 quiz 1837CrossRef
13.
go back to reference Tarsy D, Gordon L 2012 Clinical diagnostic criteria for Parkinson’s disease. In: Parkinson’s disease. CRC Press, 732–741 Tarsy D, Gordon L 2012 Clinical diagnostic criteria for Parkinson’s disease. In: Parkinson’s disease. CRC Press, 732–741
14.
go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRef Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRef
15.
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Neurosurgery, Psychiatry. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRef Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Neurosurgery, Psychiatry. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRef
16.
go back to reference El-Mewafy ZMH, Razek A, El-Eshmawy MM, El-Eneen NRA, El-Biaomy AAB (2018) Magnetic resonance spectroscopy of the frontal region in patients with metabolic syndrome: correlation with anthropometric measurement. Pol J Radiol 83:e215–e219CrossRef El-Mewafy ZMH, Razek A, El-Eshmawy MM, El-Eneen NRA, El-Biaomy AAB (2018) Magnetic resonance spectroscopy of the frontal region in patients with metabolic syndrome: correlation with anthropometric measurement. Pol J Radiol 83:e215–e219CrossRef
17.
go back to reference El-Serougy L, Abdel Razek AA, Ezzat A, Eldawoody H, El-Morsy A (2016) Assessment of diffusion tensor imaging metrics in differentiating low-grade from high-grade gliomas. Neuroradiol J 29(5):400–407CrossRef El-Serougy L, Abdel Razek AA, Ezzat A, Eldawoody H, El-Morsy A (2016) Assessment of diffusion tensor imaging metrics in differentiating low-grade from high-grade gliomas. Neuroradiol J 29(5):400–407CrossRef
18.
go back to reference Razek AA, Elmongy A, Hazem M, Zakareyia S, Gabr W (2011) Idiopathic Parkinson disease effect of levodopa on apparent diffusion coefficient value of the brain. Acad Radiol 18(1):70–73CrossRef Razek AA, Elmongy A, Hazem M, Zakareyia S, Gabr W (2011) Idiopathic Parkinson disease effect of levodopa on apparent diffusion coefficient value of the brain. Acad Radiol 18(1):70–73CrossRef
19.
go back to reference Sasaki M, Shibata E, Kudo K, Tohyama K (2008) Neuromelanin-sensitive MRI. Clin Neuroradiol 18(3):147–153CrossRef Sasaki M, Shibata E, Kudo K, Tohyama K (2008) Neuromelanin-sensitive MRI. Clin Neuroradiol 18(3):147–153CrossRef
20.
go back to reference Xing Y, Sapuan A, Dineen RA, Auer DP (2018) Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 33(11):1792–1799CrossRef Xing Y, Sapuan A, Dineen RA, Auer DP (2018) Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Mov Disord 33(11):1792–1799CrossRef
21.
go back to reference Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, Filippi M (2010) Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 75(10):857–863CrossRef Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, Filippi M (2010) Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology 75(10):857–863CrossRef
22.
go back to reference Nakamura K, Sugaya K (2014) Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res 9(7):759–760CrossRef Nakamura K, Sugaya K (2014) Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res 9(7):759–760CrossRef
23.
go back to reference Hashido T, Saito S (2016) Quantitative T1, T2, and T2* mapping and semi-quantitative neuromelanin-sensitive magnetic resonance imaging of the human midbrain. PLoS One 11(10):e0165160CrossRef Hashido T, Saito S (2016) Quantitative T1, T2, and T2* mapping and semi-quantitative neuromelanin-sensitive magnetic resonance imaging of the human midbrain. PLoS One 11(10):e0165160CrossRef
24.
go back to reference Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, Tomimoto H (2013) Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur Neurol 70(1–2):70–77CrossRef Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, Tomimoto H (2013) Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur Neurol 70(1–2):70–77CrossRef
25.
go back to reference Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, Pal PK (2018) Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Eur J Neurol 25(4):680–686CrossRef Prasad S, Stezin A, Lenka A, George L, Saini J, Yadav R, Pal PK (2018) Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Eur J Neurol 25(4):680–686CrossRef
26.
go back to reference Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP (2017) In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283(3):789–798CrossRef Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP (2017) In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283(3):789–798CrossRef
27.
go back to reference Kiebish MA, Narain NR (2019) Enabling biomarker discovery in Parkinson’s disease using multiomics: challenges, promise and the future. Per Med 16(1):5–7CrossRef Kiebish MA, Narain NR (2019) Enabling biomarker discovery in Parkinson’s disease using multiomics: challenges, promise and the future. Per Med 16(1):5–7CrossRef
28.
go back to reference Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J (2018) Tau pathology in Parkinson’s disease. Front Neurol 9:809CrossRef Zhang X, Gao F, Wang D, Li C, Fu Y, He W, Zhang J (2018) Tau pathology in Parkinson’s disease. Front Neurol 9:809CrossRef
29.
go back to reference Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161(4):1082–1090CrossRef Baquet ZC, Williams D, Brody J, Smeyne RJ (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 161(4):1082–1090CrossRef
30.
go back to reference Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal progression markers of Parkinson’s disease: current view on structural imaging. Curr Neurol Neurosci Rep 18(12):83CrossRef Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal progression markers of Parkinson’s disease: current view on structural imaging. Curr Neurol Neurosci Rep 18(12):83CrossRef
31.
go back to reference Knorle R (2018) Neuromelanin in Parkinson’s disease: from Fenton reaction to calcium signaling. Neurotox Res 33(2):515–522CrossRef Knorle R (2018) Neuromelanin in Parkinson’s disease: from Fenton reaction to calcium signaling. Neurotox Res 33(2):515–522CrossRef
32.
go back to reference Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh M, Kida H, Tomimoto H (2016) A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett 633:112–117CrossRef Matsuura K, Maeda M, Tabei KI, Umino M, Kajikawa H, Satoh M, Kida H, Tomimoto H (2016) A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett 633:112–117CrossRef
33.
go back to reference Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, Takahashi S, Kudo K, Yamashita F, Terayama Y (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541:93–98CrossRef Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, Takahashi S, Kudo K, Yamashita F, Terayama Y (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541:93–98CrossRef
34.
go back to reference Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Park Dis 5(3):561–567 Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Park Dis 5(3):561–567
35.
go back to reference Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O et al (2015) Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord 30(7):945–952CrossRef Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O et al (2015) Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord 30(7):945–952CrossRef
36.
go back to reference Takahashi H, Watanabe Y, Tanaka H et al (2018) Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson’s disease. Br J Radiol 91(1086):20180037CrossRef Takahashi H, Watanabe Y, Tanaka H et al (2018) Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson’s disease. Br J Radiol 91(1086):20180037CrossRef
37.
go back to reference Isaias IU, Trujillo P, Summers P et al (2016) Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front Aging Neurosci 8:196CrossRef Isaias IU, Trujillo P, Summers P et al (2016) Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front Aging Neurosci 8:196CrossRef
38.
go back to reference Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55(6):719–724CrossRef Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55(6):719–724CrossRef
Metadata
Title
The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis
Authors
Xiangming Wang
Yuehui Zhang
Chen Zhu
Guangzong Li
Jie Kang
Fang Chen
Ling Yang
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 12/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-04014-y

Other articles of this Issue 12/2019

Neurological Sciences 12/2019 Go to the issue